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S U M M A R Y
Objectives: The association among speciﬁc single-nucleotide polymorphisms (SNPs) in TLR2 (Arg677Trp,
Arg753Gln) and TLR4 (Asp299Gln) and human cytomegalovirus (CMV) infection was studied in infants
and adults.
Methods: The TLR2 and TLR4 polymorphisms were genotyped in 151 patients with CMV infections and in
78 unrelated healthy individuals. Genotyping was performed by restriction fragment length
polymorphism (RFLP) analysis of PCR-ampliﬁed fragments. The viral load was measured by quantitative
real-time PCR.
Results: Almost all of the patients with CMV infections were wild-type homozygotes without TLR2 and
TLR4 polymorphisms. No signiﬁcant differences in TLR2 and TLR4 polymorphisms were observed
between infants with or without CMV infection. Compared with adults with CMV infections,
heterozygosity for the TLR2 Arg677Trp and TLR4 Asp299Gly SNPs was detected more frequently in
healthy individuals (p < 0.05). Logistic regression analysis showed that the wild-type TLR2 genotype was
associated with an increased risk of CMV infection and that heterozygosity for TLR2 and TLR4 SNPs
diminished the risk of CMV infection in adult patients. An association between CMV load and the TLR4
SNP was found.
Conclusion: Our results suggest that the wild-type TLR2 genotype may be a risk factor for CMV
replication in adult patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Toll-like receptors (TLRs) are transmembrane proteins that play
a crucial role in the activation of the immune system by regulating
the production of antiviral peptides and inﬂammatory cytokines.
TLR2 and TLR4 have been shown to be involved in the innate
immune response to cytomegalovirus (CMV). Nuclear factor-kB
(NF-kB) activation and cytokine secretion is initiated after the CMV* Corresponding author. Tel.: +48 42 2723638; fax: +48 42 2723630.
E-mail addresses: eparadowska@cbm.pan.pl, etparadowska@gmail.com
(E. Paradowska).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).envelope glycoproteins B (gB) and H (gH) are detected by TLR2.1
The TLR2 Arg753Gln single-nucleotide polymorphism (SNP)
paralyzes in vitro immune signalling in cells exposed to CMV
gB.2 TLR4, endosomal TRL3, and TLR9 are also involved in CMV-
elicited signalling, which leads to a cellular proinﬂammatory and
antiviral response.3 Recent studies have shown that TLR4 is a
mediator of CMV-initiated cell cycle activation in THP-1 macro-
phages.4 Clinical evidence has demonstrated that the TLR2
Arg753Gln and the TLR4 Asp299Gly SNPs are associated with a
higher degree of susceptibility to CMV infection and disease in
transplant recipients.5–7 The homozygous CC genotype of SNP
rs3804100 in TLR2 has been found to be associated with congenital
CMV infection but not with disease.8 The importance of other
polymorphisms in the genes encoding TLR2 and TLR4 in theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Restriction enzymes and length of the restriction fragments
Gene SNP Restriction
enzyme
Allele Length of the
restriction
fragments
TLR2 Arg677Trp HpyF10VI C (wild-type) 116 bp, 20 bp
T (Arg677Trp) 136 bp
Arg753Gln MspI G (wild-type) 110 bp, 24 bp
A (Arg753Gln) 134 bp
TLR4 Asp299Gly NcoI A (wild-type) 194 bp
G (Asp299Gly) 173 bp, 21 bp
SNP, single-nucleotide polymorphism.
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strated.
In the present study, we assessed the inﬂuence of speciﬁc SNPs
in the TLR2 (Arg677Trp, Arg753Gln) and TLR4 (Asp299Gly) genes
on the risk of CMV infection in infants and adults.
This research was presented in part at the 5th European
Congress of Virology, France, Lyon, September 11–14, 2013. REF
067. Virologie 2013, 17: S137.
2. Materials and methods
Eighty-eight CMV-infected infants (age range 1–12 months,
mean 3.9 months) and 63 unrelated adults (age range 22–66 years,
mean 40.4 years) with CMV infection were enrolled in the study.
DNA isolated from peripheral blood samples obtained from CMV-
infected patients was archived during 2006 and 2011. The
distribution of TLR SNPs in CMV-infected subjects was compared
with that observed in 78 healthy subjects without CMV-speciﬁc
antibodies (including 28 infants and 50 adults) identiﬁed from the
same area. CMV infection was conﬁrmed by detecting CMV DNA
and CMV-speciﬁc antibodies in the blood samples. Symptomatic
CMV infection was observed in 74 infants (84.1%). Total genomic
DNA was extracted from blood samples using the QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany).
The TLR2 Arg677Trp (no rs number reported), TLR2 Arg753Gln
(rs5743708), and TLR4 Asp299Gly SNPs (rs4986790) were identi-
ﬁed by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP). The TLR2 and TLR4 genes were
ampliﬁed by PCR using the Taq DNA polymerase (Fermentas,
Hanover, MD, USA) and previously described primer sets.9 The
full-length PCR products were digested into the restriction
fragments listed in Table 1. The digested fragments were analyzed
using a QIAxcel DNA high-resolution gel cartridge and a QIAxcel
system (Qiagen). The genetic variants were identiﬁed by
different fragment size lengths (Table 1). The randomly selectedTable 2
Genotype frequencies and assessment of the TLR2 and TLR4 SNP genotypes as prognos
TLR SNP Genotype Genotype, n (% frequency)
Infantsa
CMV-infected Uninfected p-Va
TLR2 Arg677Trp CC 88 (100) 28 (100) 1.000
CT 0 0 
TT 0 0 
Arg753Gln GG 82 (93.2) 28 (100) 0.33
GA 4 (4.5) 0 0.57
AA 2 (2.3) 0 1.000
TLR4 Asp299Gly AA 76 (86.4) 25 (89.3) 1.000
AG 8 (9.1) 3 (10.7) 0.72
GG 4 (4.5) 0 0.57
TLR, toll-like receptor; SNP, single-nucleotide polymorphism; CMV, cytomegalovirus; n
a Risk of CMV infection in infants was not associated with TLR SNPs in an unadjuste
b The OR for CMV-infected adult patients versus uninfected adults is given.representative samples were sequenced using the MiSeq system
(Illumina, San Diego, CA, USA).
Real-time PCR quantiﬁcation of the CMV DNA copy number
(with the UL55 gene as the target template) in DNA isolates was
performed using a 7900HT Fast Real-Time PCR System (Applied
Biosystems).10
The distribution of genotypes in CMV-infected patients and
non-infected individuals was examined using Fisher’s exact test.
The Mann–Whitney U-test was used to study the association
between TLR polymorphisms and the viral load. Logistic regression
analysis was performed to obtain odds ratios (ORs) and 95%
conﬁdence intervals (95% CIs) for the association between speciﬁc
SNPs and CMV infection using unadjusted and adjusted multivari-
ate models (SPSS Inc., Chicago, IL, USA). The adjusted model
included age and symptomatic infection in infants as categorical
covariates. p-Values of 0.05 were considered statistically
signiﬁcant.
3. Results
Of the 88 infants and 63 adults with CMV infection who were
screened for the presence of the TLR2 Arg677Trp SNP, almost all of
the patients (150/151; 99.3%) were wild-type homozygotes
without this polymorphism (Table 2). No patient in either group
was homozygous for the mutation. Similarly, the majority of CMV-
infected infants and adults did not have the TLR2 Arg753Gln (82/88
(93.2%) and 62/63 (98.4%), respectively) or TLR4 Asp299Gly (76/88
(86.4%) and 59/63 (93.6%), respectively) SNPs. Nucleotide se-
quence analysis conﬁrmed the TLR variants previously identiﬁed
by PCR-RFLP. No signiﬁcant differences in the TLR2 and TLR4
polymorphisms were observed between infants with or without
viral infection, whereas the distribution was signiﬁcantly different
in CMV-infected and non-infected adult patients. The results for
TLR2 Arg677Trp showed that the wild-type CC genotype was
detected more frequently in the CMV-infected adults compared
with the seronegative participants (p < 0.001). TLR2 Arg677Trp,
TLR2 Arg753Gln, and TLR4 Asp299Gly genotyping showed that
heterozygous patients were detected more frequently in the group
of non-infected adults than in CMV-infected adults (p < 0.001,
p = 0.043, and p = 0.010, respectively; Fisher’s exact test).
The wild-type TLR2 genotype was associated with a 132-fold
(compared to Arg677Trp) and an 8-fold (compared to Arg753Gln)
increased risk of CMV infection, while heterozygosity for the TLR2
and TLR4 SNPs diminished the risk of CMV infection in adults
(Table 2). The TLR2 and TLR4 polymorphisms were not risk factors
for CMV infection (p > 0.05). No relationship between the TLR2 or
TLR4 genotype and symptomatic CMV infection in children was
observed (p > 0.05). The median level of viraemia was highertic variables for the risk of CMV disease in infants and adults
Adults
lue CMV-infected Uninfected p-Value OR (95% CI)b
 62 (98.4) 16 (32.0) <0.001 131.8 (16.7–1036.9)
1 (1.6) 34 (68.0) <0.001 0 (0–0.1)
0 0
3 62 (98.4) 44 (88.0) 0.052 8.5 (1.0–72.7)
1 1 (1.6) 6 (12.0) 0.052 0.1 (0–1.0)
 0 0
 59 (93.6) 41 (82.0) 0.064 3.2 (0.9–11.2)
5 1 (1.6) 8 (16.0) 0.022 0.1 (0–0.7)
1 3 (4.8) 1 (2.0) 0.444 2.5 (0.2–24.3)
, number of cases; OR, odds ratio; 95% CI, 95% conﬁdence interval.
d model (p > 0.05).
Table 3










3.40  102 (0–3.22  106) 0.027
Heterozygosity for the
polymorphism (AG)
0 (0–7.02  102) 0.012b
Homozygosity for the
polymorphism (GG)
1.29  102 (0–4.27  102) 0.829
a p-Values were determined by the Mann–Whitney U-test.
b CMV load was lower in patients with heterozygosity for the TLR4 Asp299Gly
SNP.
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3.40  102 copies/ml; range 0–3.22  106 copies/ml) compared
with those who were heterozygous (median 0 copies/ml; range 0–
7.02  102 copies/ml) or homozygous (median 1.29  102 copies/
ml, range 0–4.27  102 copies/ml) for this polymorphism
(p = 0.027) (Table 3). No association was observed between the
viral load and either of the TLR2 SNPs (p > 0.05).
4. Discussion
To the best of our knowledge, this is the ﬁrst report to
demonstrate that heterozygosity for the TLR2 Arg677Trp SNP is
signiﬁcantly associated with a lower risk of CMV infection in
adults. An analogous result was not observed in the infants.
Heterozygosity for the TLR4 Asp299Gly polymorphism was
detected primarily in non-infected individuals and was associated
with a lower level of viraemia. These interesting results indicate an
intriguing role for TLR SNPs in the recognition and response to CMV
infection. The TLR2 Arg677Trp and TLR4 Asp299Gly polymor-
phisms appear to be protective factors in CMV replication.
There is evidence of associations between TLR polymorphisms
and disease susceptibility and outcome, but other factors, such as
ethnicity, location, and environmental and infectious factors
contribute to the conﬂicting results reported for these associa-
tions.11 Several studies have shown signiﬁcant differences in the
allele frequency among ethnic groups for TLR2 and TLR4. The TLR2
Arg753Gln has been investigated in various populations because of
the functional consequences and its prevalence. The allele
frequency of Arg753Gln has been shown to range from 2.7% to
13.5% in different studies,5,7,9,12–16 conﬁrming differences in the
allelic frequency of this polymorphism. We found heterozygosity
for the Arg753Gln mutation in 1.6% of the CMV-infected adult
patients and in 12% of the healthy controls. In addition, this
polymorphism occurred in 6.8% of the infants with CMV infection,
which is lower than the occurrence in the Turkish population
(9.9%).17 The frequency of patients carrying a heterozygous
genotype of the TLR2 Arg677Trp in CMV-seronegative adult
patients was signiﬁcantly higher than in those with CMV infection
(68% vs. 1.6%; p < 0.001). This controversial observation provides
an insight into a new role for TLR2 and should encourage more
studies to conﬁrm our observations and to assess the other
functions of Arg677Trp and its relevance to human infection. A
high prevalence of this SNP has also been found in tuberculosis
patients (94%) and in a control population (31%).18 The Asp299Gly
SNP that encode mutations in the ectodomain of TLR4 occurs in
humans with a frequency of approximately 7% to 13%.12,19,20 In our
study, the TLR4 Asp299Gly SNP occurred more frequently in the
healthy adults compared with the CMV-infected adults (18% vs.
6.4%, respectively), although this polymorphism was observed
only in a small number of patients.Because similar TLR genotype frequencies were found in CMV-
infected and non-infected infants, we conclude that the examined
TLR2 and TLR4 SNPs have no effect on viral infection in infancy. We
suggest that the discrepancies observed in the frequency of the TLR
SNPs may depend on the age of the study population and the
immunological features of the individuals. The age-dependent
changes in innate TLR responses correlate with speciﬁc periods of
susceptibility to infection in early life and inﬂammatory diseases in
later life.21 The increased susceptibility to infection in infants
results from incompletely developed defence mechanisms, both in
innate and acquired immunity. Although TLR expression and
signalling appear similar, the TLR-mediated production of innate
immune effector molecules is reduced in early life.21 There are a
few studies that have examined the relationship between the
incidence of TLR polymorphisms and the age of the patients. It was
found that homozygosity for the TLR6 Pro249Ser genotype protects
from atherosclerosis, and a signiﬁcant increase in the frequency of
the Pro249Ser SNP with age was observed.22 Hamann et al.
speculate that this TLR6 variant may confer its beneﬁcial effects by
decreasing inﬂamm-ageing during older age.22
Little is known about the role of TLR SNPs in the pathogenesis of
CMV infection in humans. The clinical relevance of TLR2 and TLR4
polymorphism has previously been suggested only in immuno-
compromised populations.5,7,12,23 The results obtained in alloge-
neic stem cell12 and renal transplant recipients23 suggest that the
TLR2 Arg753Gln and TLR4 Asp299Gly SNPs have no signiﬁcant
effects on the incidence of CMV infection and disease. However, a
positive association between homozygosity for the TLR2
Arg753Gln SNP and the risk of CMV disease was found in patients
after liver transplantation.5,7 Kijpittayarit et al. demonstrated that
liver transplant recipients with the TLR2 Arg753Gln SNP had a
signiﬁcantly higher degree of CMV replication compared with
patients without this polymorphism.5 In our study, the wild-type
TLR2 genotype increased the risk of CMV infection in adults. A
negative correlation between heterozygosity for the TLR4
Asp299Gly SNP and CMV infection was observed. In addition,
the patients with this polymorphism in at least one allele had a
signiﬁcantly lower CMV load, while no signiﬁcant association
between TLR2 SNPs and CMV DNAemia was found. Other studies
have reported the TLR4 Asp299Gly and Thr399Ile SNPs to be
associated with a higher risk of CMV primary infection, and the
presence of these SNPs to be an independent risk factor for CMV
disease in renal transplant recipients6 and patients with advanced
HIV-1 infection.19
CMV appears to induce signalling via multiple TLRs. These
receptors can differ by being myeloid differentiation D protein 88
(MyD88)-dependent or independent, or by residing predominantly
on the cell surfaces or in endosomes. A critical role was found for
TLR2 and CD14 in CMV attachment and the activation of NF-kB in
TLR2- and CD14-overexpressing human embryonic kidney
cells.1,24 CMV envelope gB and gH interact directly with TLR2
and TLR1 during entry to initiate a signalling cascade mediated by
the adapter protein MyD88 that results in the activation of NF-kB
and the secretion of inﬂammatory cytokines.1
Gene polymorphisms located in the ectodomain of TLRs may
affect the ability of the receptor to bind pathogens, SNPs in the
transmembrane domain can lead to defects in intracellular
receptor transport, and polymorphisms in the internal domain
may result in altered interactions with adaptor proteins or in
disrupted dimerization.25,26 Moreover, polymorphism may alter
receptor expression and their activity, thereby modulating the risk
and the progression of various diseases. The infectious pressures
tend to select genetic variants of receptors that result in the strong
immune responses that are required to eliminate pathogens, but
this selection would also favour genetic variants that enhance the
inﬂammatory response.27 Hence, it may lead to greater suscepti-
A. Jabłon´ska et al. / International Journal of Infectious Diseases 25 (2014) 11–1514bility to inﬂammatory or autoimmune diseases. Such responses
may have beneﬁcial effects early in life by protecting against
infections, whereas later in life, when autoimmune diseases
become more prevalent, they may exert deleterious effects. TLR4
genetic variation has been shown to be associated with sepsis,20
malaria,28 inﬂammatory bowel disease,29 and atherosclerosis,30
while variants of TLR2 have been associated with asthma.31 It is
possible that distinct polymorphisms could be related to either a
decreased response leading to increased viral replication, or an
increased response leading to an increase in inﬂammation and
reactivation of latent virus. Evidence shows that the initiation of
CMV replication from latency is caused by immunosuppression
and also appears to be linked to activation of the immune system.
The virus can be reactivated by tumour necrosis factor alpha (TNF-
a), which is released during inﬂammation.32 TNF-a binds to the
TNF receptor on latently infected cells, generating signals that
activate NF-kB. TLR2 is capable of recognizing CMV particles
regardless of replication competence.24 Cook et al. demonstrated
that reactivation of latent murine cytomegalovirus (mCMV) is
likely a consequence of TLR4 signalling.33
Many studies have been performed attempting to link genetic
variation in TLRs with susceptibility to infectious and inﬂamma-
tory diseases. It has been found that TLR SNPs attenuate receptor
signalling and diminish the inﬂammatory response to pathogens.
Diminished signalling in cells that express polymorphic TLRs,
particularly when both mutations are expressed on the same
protein, may decrease the ability to control infection and thereby
increase susceptibility to multiple pathogens.2,22 It has previously
been found that the Arg677Trp substitution in the intracellular
MyD88-binding domain and the Arg753Gln polymorphism in the
C-terminal of TLR2 may impair the host response to microbial
pathogens.34–36 We suppose that the T allele of Arg677Trp may
affect the transcription, synthesis, and transport of TLR2 and
therefore also affect the function of TLR2 protein. Our results seem
to suggest that polymorphisms confer a protective advantage upon
individuals who carry them. The mechanisms underlying such
protections are undeﬁned, but could involve the production of
immunoregulatory cytokines. The TLR2 Arg753Gln and Arg677Trp
SNPs have both been shown to lead to decreased NF-kB and
cellular activation.15,37 We assume that the high prevalence of
TLR2 SNPs in uninfected adults is associated with decreased
susceptibility to autoimmune and inﬂammatory diseases. In
addition, other mutations or polymorphisms may account for
the protective effect of the TLR2 polymorphisms. It has previously
been shown that TLR2 SNPs are associated with protection from
various infectious diseases, e.g., aggressive periodontitis,38 Lyme
disease,13 and pulmonary tuberculosis.36
TLR2 can induce type I interferon in a subset of inﬂammatory
monocytes during infection with the vaccinia virus or mCMV.39,40
Barbalat et al. suggested that differential signalling by TLR2 may be
similar to TLR9 signalling in that different ligands produce distinct
responses through the same signalling adaptor (MyD88).39 In
addition, a specialized co-receptor might be required to generate
this speciﬁcity. TLR4 is not directly involved in CMV recognition,
but TLR4 ligands have been demonstrated to enhance the ability of
dendritic cells to present CMV antigens. This results in an increase
in the numbers of both CD4- and CD8-positive antigen-speciﬁc
activated T cells.41 The TLR4 SNP that encodes for a substitution in
the glycine for an aspartic acid at position 299 of the receptor,
alters the amino acid sequence of the TLR4 protein and affects the
extracellular domain and ligand-recognition area of the receptor.42
Importantly, the Asp299Gly allele has been associated with a
decreased risk of atherosclerosis and cardiovascular disease
(CVD).30 CMV is implicated in the pathogenesis of different CVDs,
including atherosclerosis, myocardial infarction, carotid and
coronary artery disease, and hypertension.43,44 The ﬁnding thata lower CMV load is associated with the TLR4 SNPs is consistent
with the observation that this polymorphism occurs more
frequently in cases with a reduced risk of CVD. Finally, it is also
possible that factors other than TLR polymorphisms determine
the pathogenesis of CMV infection. Further studies should
focus on how the variants might affect gene expression and
function.
In conclusion, this study suggests a potential association
between wild-type TLR2 genotype and an increased risk of CMV
infection in adults. Patients with a wild-type TLR4 genotype were
found to have higher levels of CMV replication. Further studies
with larger numbers of patients are needed to conﬁrm our unusual
observations.
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